NASDAQ:ADPT Adaptive Biotechnologies - ADPT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. $8.43 +0.59 (+7.53%) (As of 03/24/2023 08:50 PM ET) Add Compare Share Share Today's Range$7.66▼$8.4450-Day Range$7.84▼$10.1152-Week Range$5.95▼$15.19Volume1.28 million shsAverage Volume979,967 shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$13.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Adaptive Biotechnologies MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside54.2% Upside$13.00 Price TargetShort InterestBearish3.48% of Float Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment0.22Based on 7 Articles This WeekInsider TradingSelling Shares$335,977 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.15) to ($0.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector524th out of 995 stocksBiological Products, Except Diagnostic Industry92nd out of 166 stocks 3.1 Analyst's Opinion Consensus RatingAdaptive Biotechnologies has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Adaptive Biotechnologies has a forecasted upside of 54.2% from its current price of $8.43.Amount of Analyst CoverageAdaptive Biotechnologies has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.48% of the float of Adaptive Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 9.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdaptive Biotechnologies has received a 61.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Basic medical research services", "Scientific databases", and "Medical laboratory automation systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Adaptive Biotechnologies is -0.79. Previous Next 1.8 News and Social Media Coverage News SentimentAdaptive Biotechnologies has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Adaptive Biotechnologies this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for ADPT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -85% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $335,977.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions90.75% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.15) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -5.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -5.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adaptive Biotechnologies (NASDAQ:ADPT) StockAdaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.Read More Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address ADPT Stock News HeadlinesMarch 26, 2023 | msn.comAdaptive Charging may be adapting itself to Pixel users without alarmsMarch 25, 2023 | marketwatch.comLatest "Adaptive Security Market" Future Prediction Report 2023-2031March 27, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 23, 2023 | marketwatch.comAdaptive Optics Components Market Outlook by 2031March 21, 2023 | marketwatch.comGlobal Automotive Adaptive Front Lighting Market to Grow from 2023-2026March 21, 2023 | marketwatch.comThe Ultimate Research Report of Adaptive Ski Equipment Market [2023-2027] is Trending Exclusively Worldwide | Top Countries Data IncludedMarch 20, 2023 | marketwatch.comFrom 2023 to 2029 Report on the Adaptive Ski Equipment marketMarch 17, 2023 | americanbankingnews.comShort Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Grows By 9.4%March 27, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 14, 2023 | msn.comAdaptive Ski-A-Thon returns for 35th year in MaineMarch 14, 2023 | bizjournals.comMd. bio Adaptive Phage Therapeutics cutting 23% of staff to focus on clinical trials, extend cash runwayMarch 9, 2023 | finance.yahoo.comIs Fulgent Genetics (FLGT) Outperforming Other Medical Stocks This Year?March 9, 2023 | finance.yahoo.comHow Much Upside is Left in Adaptive Biotechnologies (ADPT)? Wall Street Analysts Think 49.94%February 27, 2023 | finance.yahoo.comAdaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare ConferenceFebruary 25, 2023 | nasdaq.comAdaptive Biotechnologies (ADPT) Shares Cross Below 200 DMAFebruary 24, 2023 | finance.yahoo.comKaruna (KRTX) Reports Narrower-Than-Expected Loss in Q4February 21, 2023 | finance.yahoo.comIs Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?February 21, 2023 | finance.yahoo.comCan Adaptive Biotechnologies (ADPT) Climb 45.58% to Reach the Level Wall Street Analysts Expect?February 17, 2023 | markets.businessinsider.comJ.P. Morgan Reaffirms Their Buy Rating on Adaptive Biotechnologies (ADPT)February 17, 2023 | marketwatch.comAutomotive Adaptive Suspension System Market is Booming Worldwide with Top Countries DataFebruary 16, 2023 | marketwatch.comAdaptive Learning Software Market by Top Manufacturers, Growing Demand and Supply 2023-2028February 16, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Adaptive Biotechnologies (ADPT), Royalty Pharma (RPRX) and AlloVir (ALVR)February 15, 2023 | marketwatch.comAutomotive Adaptive Lighting Market Outlook 2023 and Forecast to 2028 with Top Countries DataFebruary 15, 2023 | marketwatch.comAdaptive Optics Market To Show Incredible Growth And Forecast By 2028 Segment, Privacy Tools And Key Players InformationFebruary 15, 2023 | finance.yahoo.comAdaptive Biotechnologies (ADPT) Reports Q4 Loss, Lags Revenue EstimatesFebruary 14, 2023 | markets.businessinsider.comAdaptive Biotechnologies Q4 Loss decreases, beats estimatesFebruary 14, 2023 | finance.yahoo.comAdaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address ADPT Company Calendar Last Earnings2/14/2023Today3/27/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADPT CUSIPN/A CIK1478320 Webwww.constructionpartners.net Phone(206) 659-0067Fax206-659-0667Employees858Year Founded2009Price Target and Rating Average Stock Price Forecast$13.00 High Stock Price Forecast$17.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+54.2%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-200,190,000.00 Net Margins-108.03% Pretax Margin-108.13% Return on Equity-39.57% Return on Assets-23.51% Debt Debt-to-Equity RatioN/A Current Ratio5.12 Quick Ratio4.99 Sales & Book Value Annual Sales$185.31 million Price / Sales6.52 Cash FlowN/A Price / Cash FlowN/A Book Value$3.25 per share Price / Book2.59Miscellaneous Outstanding Shares143,230,000Free Float137,211,000Market Cap$1.21 billion OptionableNot Optionable Beta1.18 Social Links Key ExecutivesChad RobinsChairman & Chief Executive OfficerJulie RubinsteinPresidentR. Mark AdamsChief Operating OfficerTycho W. PetersonChief Financial OfficerHarlan RobinsChief Scientific OfficerKey CompetitorsReplimune GroupNASDAQ:REPLArcellxNASDAQ:ACLXIovance BiotherapeuticsNASDAQ:IOVARecursion PharmaceuticalsNASDAQ:RXRXTwist BioscienceNASDAQ:TWSTView All CompetitorsInsiders & InstitutionsETF Managers Group LLCBought 130,225 shares on 3/23/2023Ownership: 0.120%Julie RubinsteinSold 22,668 sharesTotal: $194,264.76 ($8.57/share)R Mark AdamsSold 6,529 sharesTotal: $55,953.53 ($8.57/share)Rockefeller Capital Management L.P.Sold 10,549 shares on 3/6/2023Ownership: 0.116%Stacy L TaylorSold 5,491 sharesTotal: $47,057.87 ($8.57/share)View All Insider TransactionsView All Institutional Transactions ADPT Stock - Frequently Asked Questions Should I buy or sell Adaptive Biotechnologies stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ADPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADPT, but not buy additional shares or sell existing shares. View ADPT analyst ratings or view top-rated stocks. What is Adaptive Biotechnologies' stock price forecast for 2023? 5 brokerages have issued 1-year target prices for Adaptive Biotechnologies' shares. Their ADPT share price forecasts range from $7.00 to $17.00. On average, they expect the company's share price to reach $13.00 in the next year. This suggests a possible upside of 54.2% from the stock's current price. View analysts price targets for ADPT or view top-rated stocks among Wall Street analysts. How have ADPT shares performed in 2023? Adaptive Biotechnologies' stock was trading at $7.64 at the start of the year. Since then, ADPT stock has increased by 10.3% and is now trading at $8.43. View the best growth stocks for 2023 here. When is Adaptive Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our ADPT earnings forecast. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its earnings results on Tuesday, February, 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.09. The business had revenue of $55.20 million for the quarter, compared to analysts' expectations of $55.25 million. Adaptive Biotechnologies had a negative trailing twelve-month return on equity of 39.57% and a negative net margin of 108.03%. The company's quarterly revenue was up 45.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.43) earnings per share. What ETFs hold Adaptive Biotechnologies' stock? ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ARK Genomic Revolution ETF (ARKG), Invesco Nasdaq Future Gen 200 ETF (QQQS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB). What guidance has Adaptive Biotechnologies issued on next quarter's earnings? Adaptive Biotechnologies updated its FY 2023 earnings guidance on Tuesday, February, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205.00 million-$215.00 million, compared to the consensus revenue estimate of $218.31 million. What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO? 51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA). When did Adaptive Biotechnologies IPO? (ADPT) raised $200 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. What is Adaptive Biotechnologies' stock symbol? Adaptive Biotechnologies trades on the NASDAQ under the ticker symbol "ADPT." Who are Adaptive Biotechnologies' major shareholders? Adaptive Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (6.43%), Sumitomo Mitsui Trust Holdings Inc. (3.74%), Nikko Asset Management Americas Inc. (3.74%), Geode Capital Management LLC (1.50%), Aristotle Atlantic Partners LLC (1.31%) and Price T Rowe Associates Inc. MD (1.29%). Insiders that own company stock include Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Charles Sang, David E Goel, Egon Durban, Eric Dobmeier, Euclidean Capital Llc, Francis Lo, Global Investors Lp Viking, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Kyle Piskel, Lance Baldo, Michael J Pellini, Michelle Renee Griffin, Nancy Louise Hill, Nitin Sood, R Mark Adams, Robert Hershberg, Sharon Benzeno, Stacy L Taylor and Susan Bobulsky. View institutional ownership trends. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adaptive Biotechnologies' stock price today? One share of ADPT stock can currently be purchased for approximately $8.43. How much money does Adaptive Biotechnologies make? Adaptive Biotechnologies (NASDAQ:ADPT) has a market capitalization of $1.21 billion and generates $185.31 million in revenue each year. The company earns $-200,190,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. How many employees does Adaptive Biotechnologies have? The company employs 858 workers across the globe. How can I contact Adaptive Biotechnologies? Adaptive Biotechnologies' mailing address is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. The official website for the company is www.constructionpartners.net. The company can be reached via phone at (206) 659-0067, via email at investors@adaptivebiotech.com, or via fax at 206-659-0667. This page (NASDAQ:ADPT) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.